Puma Biotech (PBYI) Tops Q4 EPS by 31c

Puma Biotech (NASDAQ: PBYI) reported Q4 EPS of $0.21, $0.31 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $51 million versus the consensus estimate of $46.85 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Cerebras Systems posts 94% revenue jump, announces OpenAI deal